Who qualifies for semaglutide as a weight-loss treatment in the UK

What the clinical evidence says about who benefits from semaglutide

The STEP 1 trial, published in the New England Journal of Medicine, enrolled adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, who did not have type 2 diabetes. Over 68 weeks, participants using semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight. That trial population closely mirrors the licensed eligibility criteria, and it tells us something useful: the people who qualified for the trial are the people for whom the evidence base exists.

There is a widespread misconception that semaglutide is mainly for people who are very severely overweight. In practice the licensed threshold starts at a BMI of 27, provided there is at least one relevant comorbidity. Conditions that count include type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea and cardiovascular disease. If you have any of those alongside a BMI in the high-20s, you may already meet the licensed criteria for a private prescription, something a prescriber will establish through assessment.

For adults with a South Asian, Chinese, Middle Eastern, Black African or African-Caribbean background, UK guidance recognises that health risks associated with excess weight arise at lower BMI values. The standard thresholds are reduced by 2.5 kg/m² for these groups, meaning a BMI of 27.5 with a qualifying condition, rather than 30, can meet the licensed criterion. This adjustment reflects real physiological differences, not a policy concession.

NHS access criteria versus private eligibility

The two routes to semaglutide operate by different rules. NICE's appraisal of Wegovy (TA875) recommends it on the NHS only within a specialist weight management service, for a maximum of two years, and generally for adults with a BMI of 35 or above and at least one weight-related comorbidity. NHS England quotes adjusted thresholds of 32.5 and above, or 27.5 to 32.4 with certain conditions, for people from the ethnic backgrounds listed above. Waiting lists for these specialist services are long in most areas.

Private prescribing follows the licensed criteria in the SmPC rather than the narrower NHS commissioning rules. That means the eligible population on a private route is broader: BMI from 27 with a qualifying condition, assessed by a clinician on the same day you apply. You can read more about what private treatment costs and what the price includes on our Wegovy cost page.

Neither route bypasses clinical assessment. A prescriber reads your answers, your medical history and your weight verification before deciding. BMI is the starting point, not the final word.

Medical histories that affect eligibility for semaglutide

Meeting the BMI threshold is necessary but not sufficient. Certain personal or family medical histories mean semaglutide is not appropriate, and a thorough prescriber will ask about all of them. A personal or family history of medullary thyroid carcinoma, or a condition called multiple endocrine neoplasia type 2, is a contraindication. A history of pancreatitis warrants careful discussion; the MHRA has highlighted acute pancreatitis as a known, if infrequent, risk with GLP-1 medicines and advises patients to seek urgent medical help for severe stomach pain that radiates to the back. Certain gastrointestinal conditions also require prescriber review.

Pregnancy, breastfeeding and trying to conceive are all situations in which semaglutide is not recommended. The medicine is not licensed for anyone under 18. For a fuller picture of situations where semaglutide may not be suitable, our page on who semaglutide does not work for goes through each in more detail.

If you are currently taking an oral contraceptive, it is worth knowing that GLP-1 medicines can affect the absorption of medicines taken by mouth, your prescriber will discuss contraception during the consultation. A guide to Wegovy qualifications in full covers this and other practical eligibility questions.

How a clinical consultation establishes whether you qualify

At nume, every consultation is read the same day by a GPhC-registered Independent Prescriber, a real clinician, not automated decision software. They look at your BMI (verified by live video), your weight-related health conditions, your medication list, your relevant medical history and any contraindications. The result is a clinical judgement, not a tick-box pass or fail.

Our clinical team's approach is to treat eligibility as a conversation rather than a threshold-crossing exercise. If semaglutide is not right for you, they will say so, and may point you toward an alternative. If you are curious about who made semaglutide and how it was developed, or want to understand who sells semaglutide and what to look for in a provider, both pages are worth reading before you decide. You can explore the range of weight-loss treatment options we offer, or read a broader overview of how semaglutide works before deciding whether to proceed. The FAQs also cover some of the more specific eligibility questions we hear regularly.

If you think you may qualify and want a clinical view, you can speak to our prescribers through a free consultation today.